What to look out for at the Alzheimer's Association International Conference
This article was originally published in Scrip
Executive Summary
New data for Roche's crenezumab and updates on novel strategies are expected to provide most interest at the upcoming Alzheimer's Association International Conference (AAIC) in Copenhagen from 12-17 July. The meeting will also hear on the progress of about trials looking at the prevention of the disease, say analysts at BioMedTracker.
You may also be interested in...
What Takeda's Failed TOMMORROW Trial Means For Early Alzheimer's Today
The TOMMORROW study was revolutionary for its time in testing Actos early, before symptoms are apparent; failure is disappointing but similar metabolic approaches might still play a role, says the Alzheimer's Association.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.